Alport Syndrome Market to Expand at a Remarkable 47% CAGR Through 2036

The Alport syndrome market is poised for substantial expansion through 2036, supported by advances in genetic diagnostics, rising disease awareness, improved identification of hereditary kidney disorders, and the development of innovative treatment approaches. The evolving therapeutic pipeline includes promising candidates such as ELX-02 (Exaluren) from Eloxx Pharmaceuticals, Vonafexor from Enyo Pharma, BAY3401016 from Evotec and Bayer, Setanaxib from Asahi Kasei, Atrasentan (VANRAFIA) from Novartis (Chinook Therapeutics), and several other investigational therapies.

LAS VEGAS, July 14, 2026 /PRNewswire/ -- DelveInsight’s recently published Alport Syndrome Market Insights report provides an in-depth assessment of the current treatment landscape, emerging therapies, individual treatment market shares, and historical and forecasted market size from 2022 to 2036. The analysis covers the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Recent Developments in the Alport Syndrome Market

• According to the March 2026 annual report, the Phase IIa study of exaluren in nonsense mutation-associated syndromes, disorders, or diseases has been completed. A Phase IIb study was planned for the first half of 2026, subject to patient enrollment and funding availability. Topline results from the 16-week placebo-controlled period are expected by mid-2027, while the final study readout is anticipated by the end of 2027. However, the company currently does not have adequate funding to support the planned Phase IIb Alport syndrome study.
• In January 2026, ENYO Pharma reported positive topline results from the Phase II ALPESTRIA-1 trial, indicating that vonafexor slowed the decline in kidney function and provided sustained therapeutic benefits in patients with Alport syndrome.
• Also in January 2026, ENYO Pharma announced plans for an End-of-Phase II meeting with regulators in Q2 2026, ahead of a proposed Phase III Alport syndrome study targeted for initiation in the second half of 2026.

Alport Syndrome Market Summary

The Alport syndrome market was valued at approximately USD 27 million across the 7MM in 2025. The United States represented the dominant market, contributing nearly 88% of the total Alport syndrome treatment market in the 7MM during the same year, substantially exceeding the contributions from the EU4, the United Kingdom, and Japan.

Approximately 203,800 prevalent cases of Alport syndrome were estimated across the 7MM in 2025, with the patient population projected to increase through 2036. The expanding pipeline is being advanced by companies including Eloxx Pharmaceuticals, Enyo Pharma, Evotec, Bayer, Asahi Kasei, Novartis (Chinook Therapeutics), Travere Therapeutics, Renalys Pharma, ZyVersa Therapeutics, River 3 Renal, Bain Capital Life Sciences, and others.

Key investigational therapies that could influence the future Alport syndrome treatment landscape include ELX-02 (Exaluren), Vonafexor, BAY3401016, Setanaxib, Atrasentan (VANRAFIA), Sparsentan (FILSPARI), VAR 200, R3R01, and other emerging candidates.

Discover Alport syndrome new treatment @ https://www.delveinsight.com/report-store/alport-syndrome-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key Factors Driving the Growth of the Alport Syndrome Market

Growing Disease Awareness and Advances in Genetic Diagnosis: Greater recognition of Alport syndrome among physicians and patients, combined with improvements in genetic testing and next-generation sequencing technologies, is facilitating earlier and more accurate diagnosis. Enhanced diagnostic capabilities can support timely disease management and help identify affected family members.

Increasing Focus on Precision Medicine: The growing adoption of precision medicine is encouraging researchers to develop treatments designed around specific genetic abnormalities associated with Alport syndrome. Mutation-directed therapeutic strategies could improve treatment outcomes while opening additional commercial opportunities for pharmaceutical and biotechnology companies.